Alpharadin (radium-223 Chloride) Improves Prostate Cancer Patient Survival Considerably
9/24/2011
Alpharadin (radium-223 chloride) was found to improve overall survival by patients with CRPC (castration-resistant prostate cancer) and symptomatic bone metastases - survival rates improved by 44%, presenters explained at the Presidential Session at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden...
Treatment Of Rectal Cancer Varies Considerably Across European Countries
9/24/2011
Across European countries the use of chemotherapy and radiotherapy differs considerably, according to the primary results from an international comparison of the care of patients with rectal cancer...
Bayer HealthCare Pharmaceuticals announced that the investigational drug radium-223 chloride showed positive data in the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial. The study met its primary endpoint by significantly improving overall survival by 44% (p=0.00185, HR=0.695) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases...
Protein 'Switches' Could Turn Cancer Cells Into Tiny Chemotherapy Factories
9/24/2011
Johns Hopkins researchers have devised a protein "switch" that instructs cancer cells to produce their own anti-cancer medication. In lab tests, the researchers showed that these switches, working from inside the cells, can activate a powerful cell-killing drug when the device detects a marker linked to cancer...
System Developed That Finds Prostate Cancer Spread Earlier Than Conventional Imaging
9/24/2011
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a way to image the spread of a particularly dangerous form of prostate cancer earlier than conventional imaging in use today, which may allow oncologists to find and treat these metastases more quickly and give patients a better chance at survival...
Two New Risk Indicators For Prostate Cancer Revealed
9/24/2011
Today, at the 2011 European Multidisciplinary Cancer Congress, two new risk indicators for prostate cancer will be revealed. The investigation, led by Dr David Orsted at the Copenhagen University Hospital, Herlev, reveals that men who are diagnosed with benign prostate enlargement have a higher risk of developing and dying from prostate cancer...
Duration Of Anesthesia Doesn't Affect Risk Of Developing Cancer
9/24/2011
Helping to allay fears raised by previous studies, a new report finds no link between the duration or depth of general anesthesia and the subsequent risk of developing cancer, according to the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS)...
Extra Months Of Disease-Free Life For Melanoma Patients Delivered By New Treatment
9/24/2011
Once melanoma of the eye (ocular or uveal melanoma) spreads to the liver, which happens frequently, no effective treatment is available and often the individuals die within two to four months on average, with only one in ten surviving for a year...
According to an investigation reported today at the 2011 European Multidisciplinary Cancer Congress, individuals suffering with bone metastases from advanced prostate cancer have not had many options until recently. Now the first Phase II investigation of an alpha-pharmaceutical in these individuals has revealed that it can extend survival considerably. Dr...
Researchers Identify New Genes That Determine Breast Cancer Prognosis
9/24/2011
Researchers at Wake Forest Baptist Medical Center have made a discovery that brings them one step closer to being able to better predict which patients have the best chance of surviving breast cancer. The group has identified 16 genes, or proteins, all involved in iron metabolism, that provide better prognostic information than conventional, standard markers of prognosis...